Impact of Amantadine on Traumatic Brain Injury

• Status: Recruiting
• Trial end date: 2021-10-05
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to evaluate whether the addition of amantadine to the management regimen of traumatic brain injury patients would have a favorable effect on recovery and neurological complications in association with prognosis biomarkers Interleukin-18 (IL-18), Neuron-specific enolase (NSE) and (Neurotensin).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Damanhour University
• Treatments: Amantadine

Criteria

• Inclusion criteria

•Adult patients will be enrolled if they present with clinical signs of trauma brain injury

• Exclusion criteria

• Age lower than 18

• Females with positive pregnancy test

• Known congestive heart failure or ischemic heart disease

• Any injury disturbs the examination (high cervical cord injury or locked-in syndrome, could be a source of bias)

• Penetrating head trauma

• Need for any operation (laparotomy or craniotomy)

• Severe brain disease (For example CVA history or brain tumour)

• Renal failure with GFR lower than 60 ml/min

• Patients with unknown identity